The history of Viagra presents a interesting case for observers in the pharmaceutical sector. While initially a phenomenal success, producing vast sums, the intellectual property end and the subsequent entry of off-brand alternatives have significantly changed income. This raises questions about the ongoing sustainability of related medication deve